The health tech startup Mamotest announced the closing of its Pre Series A for 3.3 million dollars. The round was led by J&J Impact Venturesan impact fund part of the Johnson & Johnson Foundationwith the participation of VC Sonen Capital, Sky High and other private investors.
With this Mamotest already reaches a total investment of 5 million dollars.
What does Mamotest do?
Mamotest is a technology company founded in 2013 with impact that developed the only telediagnosis platform for mammograms and cancer patient guidance supported by artificial intelligence. His vision is to create a health system that keeps us healthy and his purpose is to drastically reduce deaths from breast cancer.
With a strong presence in Mexico and Argentina, Mamotest’s impact and reach have been recognized by some of the most important organizations in the world. In the past year alone, she has been elected:
- One of the most innovative companies in the world (#8 in Latam) according to the magazine Fast Company
- One of the most disruptive global health startups according to the United Nations
- Part of the 100 companies that can save 1 billion lives by the Norrsken Foundation
- Winner of the Zayed Sustainability Prize (United Arab Emirates)
- Tech Partner of the World Economic Forum
In addition, 2022 was a key year for Mamotest because it marked the launch of its most recent technological development: its own digital platform that combines the latest advances in artificial intelligence with a 100% patient-focused approach. With it, Mamotest reached more than half a million women —regardless of their resources— and 3,500 health professionals, providing 100% traceability of the patient and generating data that already saves lives: thanks to this technology, 87% of women Diagnosed with 5 million breast cancer accessed treatment on time.
Editorial Team The editorial team of EMPRENDEDOR.com, which for more than 27 years has worked to promote entrepreneurship.